Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)
Helicobacter Jul 16, 2019
Auttajaroon J, et al. - In this prospective randomized pilot study, researchers assessed a once-daily dosing H. pylori eradication regimen. The compared a once-daily treatment regimen containing levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg) for 7 or 14 days. A full 100 participants were randomized. High eradication rate was achieved with once-daily 14-day rabeprazole-, levofloxacin-, clarithromycin-MR-, and bismuth-containing therapy— suggesting the high efficacy of triple therapies with a proton-pump inhibitor, bismuth, and clarithromycin-MR or levofloxacin for once-a-day tailored therapy or as empiric therapy for first-line regimen.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins